CASI Pharmaceuticals, Inc (DE) financial data

Industry
Biological Products, (No Diagnostic Substances)
Location
9620 Medical Center Dr, Ste 300, Rockville, MD
State of incorporation
DE
Fiscal year end
December 31
Former names
CASI Pharmaceuticals, Inc. (to 2/21/2023), ENTREMED INC (to 6/13/2014)
Latest financial report
Apr 26, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 304 % -57.3%
Quick Ratio 29 % +24%
Debt-to-equity 54 % +79.7%
Return On Equity -66.1 % -65%
Return On Assets -34.7 % -34.3%
Operating Margin -79 % +42.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 13.5M shares
Common Stock, Shares, Outstanding 13.5M shares -3.73%
Common Stock, Value, Issued 1K USD 0%
Weighted Average Number of Shares Outstanding, Basic 13.6M shares +0.27%
Weighted Average Number of Shares Outstanding, Diluted 13.6M shares +0.27%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 43.1M USD +42.9%
Revenue from Contract with Customer, Excluding Assessed Tax 38M USD +26.7%
Selling and Marketing Expense 14.3M USD -2.58%
General and Administrative Expense 23.4M USD -1.06%
Costs and Expenses 61.3M USD +3.7%
Operating Income (Loss) -34M USD +18%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -26.3M USD +49.9%
Net Income (Loss) Attributable to Parent -41M USD -11.9%
Earnings Per Share, Basic -3.01 USD/shares -11.9%
Earnings Per Share, Diluted -3.01 USD/shares -11.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 47.1M USD +21.7%
Accounts Receivable, after Allowance for Credit Loss, Current 13M USD +32.3%
Inventory, Net 6.14M USD +222%
Assets, Current 73.4M USD +18.5%
Property, Plant and Equipment, Net 11.8M USD -6.93%
Operating Lease, Right-of-Use Asset 1.4M USD -84.6%
Intangible Assets, Net (Excluding Goodwill) 1.06M USD -91.3%
Other Assets, Noncurrent 1.06M USD -51.5%
Assets 96.2M USD -30.4%
Accounts Payable, Current 3.29M USD +48%
Liabilities, Current 17M USD +29%
Operating Lease, Liability, Noncurrent 476K USD -56.9%
Other Liabilities, Noncurrent 12.3M USD -14.2%
Liabilities 29.3M USD -3.42%
Accumulated Other Comprehensive Income (Loss), Net of Tax -703K USD -136%
Retained Earnings (Accumulated Deficit) -637M USD -5.2%
Stockholders' Equity Attributable to Parent 44.6M USD -47.3%
Liabilities and Equity 96.2M USD -30.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.24M USD +47%
Net Cash Provided by (Used in) Financing Activities -3M USD -110%
Net Cash Provided by (Used in) Investing Activities -2.29M USD +81%
Common Stock, Shares Authorized 500M shares +100%
Common Stock, Shares, Issued 13.7M shares -1.82%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -9.45M USD -185%
Deferred Tax Assets, Valuation Allowance 85.5M USD +2.22%
Operating Lease, Liability 1.34M USD -38%
Payments to Acquire Property, Plant, and Equipment 2.29M USD +133%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -34.2M USD -1.18%
Lessee, Operating Lease, Liability, to be Paid 1.38M USD -38.8%
Property, Plant and Equipment, Gross 14.1M USD -5.52%
Operating Lease, Liability, Current 868K USD -18.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 470K USD -39.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 899K USD -19.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 37K USD -58.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 10K USD -97.2%
Deferred Tax Assets, Operating Loss Carryforwards 65.5M USD -6.06%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 997K USD -30.8%
Operating Lease, Payments 323K USD -12.7%
Additional Paid in Capital 692M USD -0.64%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 341K USD +1.19%
Deferred Tax Assets, Net of Valuation Allowance 2.23M USD -49.4%
Preferred Stock, Par or Stated Value Per Share 1 USD/shares 0%